Phibro Animal Health (NASDAQ:PAHC) Lowered to “Hold” Rating by Zacks Research

Zacks Research downgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a strong-buy rating to a hold rating in a report published on Thursday morning,Zacks.com reports. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.68 EPS, FY2026 earnings at $3.04 EPS, Q2 2027 earnings at $0.84 EPS, Q3 2027 earnings at $0.75 EPS, Q4 2027 earnings at $0.80 EPS, FY2027 earnings at $3.17 EPS, Q1 2028 earnings at $0.81 EPS, Q2 2028 earnings at $0.91 EPS, Q3 2028 earnings at $0.81 EPS and FY2028 earnings at $3.34 EPS.

A number of other brokerages also recently issued reports on PAHC. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 8th. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research note on Friday, February 6th. Finally, Citigroup dropped their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $38.80.

Phibro Animal Health Trading Down 0.6%

NASDAQ:PAHC opened at $33.26 on Thursday. Phibro Animal Health has a one year low of $22.51 and a one year high of $60.08. The business has a fifty day moving average price of $50.29 and a 200-day moving average price of $45.99. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of 14.27, a price-to-earnings-growth ratio of 0.51 and a beta of 0.61. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.04. The company had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Sell-side analysts forecast that Phibro Animal Health will post 3.07 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.4%. Phibro Animal Health’s dividend payout ratio is currently 20.60%.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total value of $219,562.72. Following the sale, the chief executive officer owned 56,152 shares in the company, valued at $2,722,810.48. The trade was a 7.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 89,008 shares of company stock valued at $4,757,177. Insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

Several large investors have recently made changes to their positions in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after buying an additional 546 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock valued at $724,000 after acquiring an additional 13,404 shares during the last quarter. Cetera Investment Advisers boosted its position in shares of Phibro Animal Health by 63.0% during the 2nd quarter. Cetera Investment Advisers now owns 18,830 shares of the company’s stock valued at $481,000 after acquiring an additional 7,280 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after purchasing an additional 363 shares in the last quarter. 99.34% of the stock is owned by institutional investors.

Trending Headlines about Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks Research raised its earnings estimates for multiple future periods, including FY2026, FY2027, and FY2028, while reiterating a Strong-Buy rating on Phibro Animal Health (NASDAQ:PAHC), which could support sentiment around the stock.
• Neutral Sentiment: Phibro announced it will participate in the Stifel Jaws & Paws Conference on May 27, giving management another opportunity to discuss strategy and outlook with investors. Article Title
• Negative Sentiment: Despite the upgraded earnings forecasts, the stock is still facing pressure from a Citi price-target cut to $44 from $62 earlier in the week, which may be weighing on shares and signaling concerns about sector conditions. Article Title

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.